2-吗啉-4-基-4-苯基噻唑-5-甲酸 | 188679-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-吗啉-4-基-4-苯基噻唑-5-甲酸
• 中文别名: 2-吗啉-4-基-4-苯基-噻唑-5-羧酸
• 英文名称: 2-(N-morpholino)-4-phenyl-5-thiazolecarboxylic acid
• 英文别名: 2-Morpholin-4-YL-4-phenylthiazole-5-carboxylic acid；2-morpholin-4-yl-4-phenyl-1,3-thiazole-5-carboxylic acid
• CAS: 188679-21-2
• 化学式: C₁₄H₁₄N₂O₃S
• mdl: MFCD09260340
• 分子量: 290.343
• InChiKey: VGBQZSUJYCGPPM-UHFFFAOYSA-N

物化性质

• 沸点：
  495.1±55.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  90.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Azole-phenyl urea derivatives as ACAT inhibitors and their production
  申请人：NIHON NOHYAKU CO., LTD.

  公开号：EP0761658A1

  公开（公告）日：1997-03-12

  The present invention relates to azole-phenyl urea derivatives represented by the general formula (I): [wherein each of R1, R2 and R3 is H, halogen, C1-8alkyl or the like, and A is a group represented by the formula (i) or (ii): (wherein R4, R5, R6 and X are as defined in the specification.)] and a pharmacologically acceptable salt thereof, which have ACAT-inhibitory activity and are useful as a prophylactic and therapeutic agent for hypercholesterolemia, atherosclerosis and various diseases caused by them; a process for producing said derivative; and an ACAT inhibitor containing said derivative or salt as an active ingredient.

  本发明涉及一种由通式（I）表示的唑-苯基脲衍生物： [其中R1、R2和R3中的每一个是H、卤素、C1-8烷基或类似物，A是由式（i）或（ii）表示的基团： （其中R4、R5、R6和X如规范中定义。）]及其药理学上可接受的盐，具有ACAT抑制活性，并可用作高胆固醇血症、动脉粥样硬化及由其引起的各种疾病的预防和治疗剂；生产该衍生物的方法；以及含有该衍生物或盐作为活性成分的ACAT抑制剂。
• [EN] HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAIN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS CIBLANT LE DOMAINE DE LIAISON À L'ADN (DBD) DU RÉCEPTEUR DES ANDROGÈNES HUMAIN SERVANT D'AGENTS THÉRAPEUTIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2015120543A1

  公开（公告）日：2015-08-20

  A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-mcmbcrcd heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or blader cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds arc also described.

  一种具有公式I结构的化合物，其中A是取代或未取代的芳基或杂芳基基团，D是取代或未取代的5-或6-成员杂芳基或杂环基基团，E是取代或未取代的芳基，杂芳基，环烷基或杂环基基团。这些化合物用于治疗雄激素调节的症状，包括癌症（前列腺，乳腺，卵巢，子宫内膜或膀胱癌），脱发，痤疮，多毛症，卵巢囊肿，多囊卵巢综合症，早熟和年龄相关性黄斑变性。还描述了使用这些化合物制造调节雄激素受体活性的药物、使用这些化合物的治疗方法、以及包含这些化合物的制药组合物和商业包装。